ArticleJournal of translational medicine2026
Antitumor effects of the novel docetaxel derivative JJH201601 in glioma: targeting ribosome biogenesis and enhancing temozolomide sensitivity.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGlioma is a highly aggressive brain tumor with few therapy options. Temozolomide (TMZ) is a standard chemotherapeutic medication, although its effectiveness is limited by innate and acquired drug resistance.
methodsA series of functional properties were assessed using established glioma cell lines (U87, LN229) and patient-derived subtypes, to investigate cell survival, colony formation, apoptosis, EdU incorporation, and cell cycle distribution. Treatment responses were assessed in a therapeutically relevant setting using glioma organoid models to investigate the synergistic effects of JJH201601 with TMZ, a CDC7 inhibitor (XL413), and a CDK4/6 inhibitor (palbociclib). For pharmacological investigations, glioma xenograft models in nude mice were created by inoculating U87 cells subcutaneously.
resultsJJH201601 dramatically reduced cell viability, induced apoptosis, and caused G1/S transition dysregulation with S-phase accumulation in glioma cells. It suppressed ribosome-related genes (RPL13, RPS9, and RPS27L) while activating the p53 signaling pathway. The combination therapy with TMZ had a synergistic inhibitory effect on tumor growth in both cell lines and glioma organoids. JJH201601 boosted the antiproliferative effects of CDK4/6 and CDC7 inhibitors by lowering Ki-67 expression and disrupting cell cycle checkpoint regulation. JJH201601 has an impact on key glioma cell survival regulators, including CDK2, γ-H2AX, and MCM2, as determined by transcriptome analyses. JJH201601 also had a substantial inhibitory effect on recurrent primary glioma cells.
conclusionsJJH201601 exhibited anti-glioma activity by suppressing proliferation, promoting apoptosis, affecting ribosome biogenesis-related signaling, and disrupting cell cycle regulation. Its combination with TMZ and selected cell cycle inhibitors showed enhanced inhibitory effects in preclinical glioma models. However, current in vivo evidence is restricted to a subcutaneous xenografts, further orthotopic intracranial glioma studies with pharmacokinetic profiling and comprehensive safety assessments are required to confirm its efficacy for resistant glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.